The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biomarkers in Rheumatoid Arthritis Remain Elusive

Biomarkers in Rheumatoid Arthritis Remain Elusive

February 1, 2015 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Research (Abstract 2973) presented at the 2014 ACR/ARHP Annual Meeting included 143 patients in the BRASS registry at Harvard who had received a stable treatment over two years. They were evaluated at a single visit in the BRASS registry for the Vectra DA score and the conventional measures of CRP, DAS28-CRP, CDAI, SDAI and RAPID3. X-rays of their hands and wrists were obtained at the visit and two years later. Vectra DA was a better predictor of radiographic progression over two years when compared with the standard measures based on the exam or patient-reported outcomes. The odds ratio for predicting progression was highest for Vectra DA and lowest for RAPID3.

You Might Also Like
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
Explore This Issue
February 2015
Also By This Author
  • Is It Time to Replace the HAQ?

Eric Sasso, MD, vice president of medical and scientific affairs at Crescendo Bioscience, says the research indicates that a high Vectra DA score can occur even when CRP for conventional clinical measures show low disease activity or even remission. “When those types of discordance occur (i.e., high Vectra score indicating high disease activity in a patient with low CRP or low clinical measure of disease activity), those patients have an increased risk of ongoing joint damage.” These findings, he says, suggest that the Vectra DA test is detecting disease in some patients who appear to be in remission.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Vectra can provide additional information not readily available from conventional assessments, he says, such as when a patient appears to be in remission but actually has a risk of further joint damage. It can also be useful in the opposite kind of situation where the patient has a great deal of pain and appears to be doing poorly. “In some cases, the pain may be noninflammatory and the patient may not have much or any activity of their RA,” Dr. Sasso says. “Vectra DA can provide a completely objective way of assessing the contribution of rheumatoid inflammation.

“The role of Vectra DA is to measure the amount of disease activity. That information can be particularly important when deciding whether to change treatment, and the result can provide assurance as to whether the patient is doing well on current therapy,” Dr. Sasso says. “Vectra DA does not help with the decision about which therapy to select. That remains an area of great interest for ongoing research.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Ruderman noted that rheumatologists who use Vectra do so to help them rule or rule out active disease and to quantify active disease. Those who don’t use it, he says, think it is an interesting approach but may not be much better than what they are currently using, such as CRP and DAS28 or a swollen and painful joint exam, which can be less expensive.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biomarkers, Holliman, Rheumatoid arthritisIssue: February 2015

You Might Also Like:
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)